Mergers & Acquisitions - Ophthalmics, Oncology

Filter

Current filters:

OphthalmicsOncology

Popular Filters

1 to 25 of 2269 results

First Asian approval for ophthalmic drug Jetrea, in Malaysia

18-04-2014

Belgian biotech firm ThromboGenics NV revealed today that Jetrea (ocriplasmin) has been approved in Malaysia…

AlconAsia-PacificBiotechnologyJetreaMalaysiaNovartisOphthalmicsRegulationThromboGenics

OPKO to buy Israel’s Inspiro, gaining rights to new drug delivery technology

18-04-2014

US biopharma company OPKO Health has entered into a definitive agreement to acquire Inspiro Medical an…

Inspiro MedicalMergers & AcquisitionsOPKO HealthPharmaceuticalRespiratory and Pulmonary

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

17-04-2014

Family-owned US chemical developer and manufacturer SI Group has signed a deal to acquire the antioxidants,…

AlbemarleAnalgesiaibuprofenMergers & AcquisitionsPharmaceuticalUSA

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

Potential to fast-track drugs in new Cancer Research UK partnership with AstraZeneca and Pfizer

17-04-2014

British charity Cancer Research UK has joined forces with Anglo-Swedish drug major AstraZeneca and US…

AstraZenecaCancerHealthMajorMedicineOncologyPfizerPharmaceuticalPharmacologyResearchUK

Epirus to acquire Zalicus, creating a publicly-traded biosimilars enterprise

16-04-2014

Boston-based privately-held Epirus Biopharmaceuticals, focused on the global development and commercialization…

BiosimilarsBiotechnologyEPIRUS BiopharmaceuticalsMergers & AcquisitionsZalicus

EMA says that vials of falsified Herceptin have been identified

EMA says that vials of falsified Herceptin have been identified

16-04-2014

The European Medicines Agency says it has been informed that vials of Swiss drug major Roche’s blockbuster…

EuropeHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

16-04-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget today announced their intention…

belinostatBioAlliance PharmaLivatagMergers & AcquisitionsOncologyPharmaceuticalRare diseasesTopotarget

Bio-Techne to acquire China’s PrimeGene

15-04-2014

Techne Corp (d/b/a Bio-Techne) says that its R&D Systems China subsidiary has entered into an agreement…

Bio-TechneBiotechnologyMergers & AcquisitionsPrimeGene Bio-Tech

FTC imposes conditions on Akorn’s proposed buy of Hi-Tech Pharmacal

15-04-2014

In order to consummate the proposed $640 million acquisition of Hi-Tech Pharmacal by fellow USA-based…

ActavisAkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth AmericaUSA

NeoStem to acquire California Stem Cell, expanding pipeline

14-04-2014

USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

Immune responses enhanced and sustained when Provenge is given after ADT in prostate cancer

12-04-2014

US biotech firm Dendreon has released positive preliminary data from a long-term analysis of the Phase…

BiotechnologyDendreonOncologyProvengeResearch

Chugai files NDA for vemurafenib for melanoma

Chugai files NDA for vemurafenib for melanoma

11-04-2014

Japanese drugmaker Chugai Pharmaceutical has filed a new drug application to the Ministry of Health,…

BRAFV600ChemistryChugai PharmaceuticalJapanJO28178OncologyOrganochloridesPharmaceuticalRegulationRoche Diagnosticsvemurafenib

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11-04-2014

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

BiotechnologyEuropeGilead SciencesidelalisibImbruvicaJohnson & JohnsonMarkets & MarketingOncologyUSA

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

Erytech adds a new product candidate to its development portfolio

10-04-2014

French cancer focused drug developer Erytech Pharma has added a new product development candidate, ERY-MET,…

ERY-METErytech PharmaOncologyPharmaceuticalResearch

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

1 to 25 of 2269 results

Company Spotlight

Fibrotech

Fibrotech

Back to top